The U.S. Food and Drug Administration has accepted for priority review the Biologics License Application (BLA) for Sanofi’s investigational therapy efanesoctocog alfa (BIVV001).
BIVV001 is a recombinant factor VIII therapy (rFVIII) developed for…
The National Hemophilia Foundation is proud to support the second-annual Telehealth Awareness Week presented by the American Telemedicine Association! Telehealth continues to play a critical role in supporting access to safe, quality healthcare…
The National Hemophilia Foundation (NHF) and Medscape are pleased to announce the first live activity in a Virtual Grand Round Series on “Gene Therapy for Patients with Hemophilia.”
The program, presented through a collaboration between the NHF…
Apply by Sept. 23 to join one of four NBDF task forces focused on health equity, diversity, and inclusion. Task forces include focuses on access, mental health, health system navigation, and payer/policy. Click the button to fill out an application…
FOR IMMEDIATE RELEASEOn Saturday, September 10, 2022, BioMarin announced that a hemophilia A patient participating in a gene therapy clinical trial – in which they had been treated with BMN270 – has been diagnosed with pre B cell…
This week, a Peoria Illinois jury awarded reputation-related damages in favor of Dr. Osvaldo Wesly and against the National Hemophilia Foundation. The claim stems from an incident dating back to 2014. Our attorneys plan to appeal the decision.…
NHF’s Washington Days is an opportunity for people affected by inherited blood disorders to advocate for issues that are important to them. In 2021, Washington Days had more than 400 volunteer advocates from 45 states that met with legislators and…
Dejah uses her NYLI experience to lead others as she pursues her master’s degree in biology. Learn about her story here!
Tell us about yourself!
My name is Dejah Smith, I’m 24 and I’m a Microbial Genomics Researcher at East Carolina…
Joseph expanded his role at his local NHF chapter with the skills he learned through NYLI. Learn more about his journey!
Tell us about yourself.
Hi! My name is Joseph Mah, I’m 22 and I’m a Biomechanics Analyst at the Colorado Hemophilia and…